Coronavirus-Like Particle COVID-19 Vaccine

Coronavirus-Like Particle COVID-19 Vaccine Uses, Dosage, Side Effects, Food Interaction and all others data.

The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. VLPs are thought to have multiple mechanisms involving the immune system which engage both humoral and cellular responses. In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as ISS-1018), meant to provide an enhanced immune response to the vaccine. In addition, Medicago partnered with GlaxoSmithKline (GSK) to test its adjuvant, AS03. A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged 18-55 years.

Trade Name Coronavirus-Like Particle COVID-19 Vaccine
Generic Coronavirus-Like Particle COVID-19 Vaccine
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Coronavirus-Like Particle COVID-19 Vaccine
Coronavirus-Like Particle COVID-19 Vaccine

Innovators Monograph

You find simplified version here Coronavirus-Like Particle COVID-19 Vaccine


*** Taking medicines without doctor's advice can cause long-term problems.
Share